212 related articles for article (PubMed ID: 29491310)
1. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
Shiba M; Inaba H; Ariyasu H; Kawai S; Inagaki Y; Matsuno S; Iwakura H; Yamamoto Y; Nishi M; Akamizu T
Intern Med; 2018 Jul; 57(14):2029-2034. PubMed ID: 29491310
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
3. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab in advanced melanoma.
Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
[TBL] [Abstract][Full Text] [Related]
5. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
7. A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms.
Ishikawa K; Shono-Saito T; Yamate T; Kai Y; Sakai T; Shimizu F; Yamada Y; Mori H; Noso S; Ikegami H; Kojima H; Tanaka H; Fujiwara S; Hatano Y
Eur J Dermatol; 2017 Apr; 27(2):184-185. PubMed ID: 27934619
[No Abstract] [Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Gauci ML; Boudou P; Baroudjian B; Vidal-Trecan T; Da Meda L; Madelaine-Chambrin I; Basset-Seguin N; Bagot M; Pages C; Mourah S; Resche-Rigon M; Pinel S; Sassier M; Rouby F; Eftekhari P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
[TBL] [Abstract][Full Text] [Related]
11. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
15. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade.
Naidoo J; Page DB; Wolchok JD
Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
18. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
19. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
20. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]